Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Intravenous administration for fluid and electrolyte replacement in patients with deficits of water and electrolytes,Maintenance of fluid and electrolyte balance when oral intake is inadequate,Treatment of hypovolemia (low blood volume) due to various causes such as dehydration, burns, or surgery
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable as a fixed value; infused electrolytes distribute and are eliminated according to individual ion kinetics (e.g., sodium t½ ~30 min, chloride t½ ~1–2 h) with rapid redistribution.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
PLASMA-LYTE 56 is a crystalloid solution; its components are not metabolized. Electrolytes are distributed and eliminated via renal excretion and normal physiological pathways. The solution itself is not subject to hepatic metabolism.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Primarily renal; >90% of infused electrolytes are excreted unchanged in urine; fecal elimination negligible (<5%).
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Minimal (<5%); electrolytes (Na+, Cl-, K+, Mg2+, acetate, gluconate) are not significantly protein-bound.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Approximately 0.2–0.3 L/kg for sodium and chloride, corresponding to extracellular fluid volume; distributed throughout ECF.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
100% by intravenous route; not administered orally (bioavailability not applicable).
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of potassium and magnesium accumulation; use with caution and monitor electrolytes in moderate impairment (GFR 30-59 m L/min).
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific adjustment required; however, monitor electrolytes in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Dose based on weight and clinical status; typical initial infusion rate: 5-10 m L/kg/hour, adjusted based on response and electrolyte monitoring.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Use with caution due to reduced renal function; start at lower infusion rates (e.g., 50-100 m L/hour) and monitor for fluid overload and electrolyte disturbances.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
No black box warning is provided for this drug.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload (e.g., congestive heart failure, pulmonary edema),Monitor electrolytes, fluid balance, and renal function during administration,Avoid in patients with hypervolemia, since this may exacerbate fluid overload conditions,Use with caution in patients receiving corticosteroids or corticotropin, as they may increase risk of fluid and electrolyte disturbances,Solutions containing acetate should be used with caution in patients with hepatic insufficiency
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hypersensitivity to any component of the solution,Clinically significant hypervolemia (fluid overload),Hyperkalemia (for solutions containing potassium),Severe renal impairment (anuria or oliguria) unless dialysis is performed,Acute or chronic metabolic alkalosis (for solutions containing acetate)
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No specific food interactions; maintain normal diet unless otherwise directed by physician. Avoid excessive potassium-rich foods if renal impairment exists.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Excreted into breast milk in negligible amounts; considered compatible with breastfeeding. M/P ratio not applicable as endogenous electrolytes.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No specific dose adjustments during pregnancy. Use standard dosing based on clinical status; avoid fluid overload in preeclampsia or cardiac conditions.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Plasma-Lyte 56 is a balanced crystalloid solution containing acetate and gluconate as buffers, which may reduce the risk of hyperchloremic metabolic acidosis compared to 0.9% saline. It is isotonic (osmolarity 406 m Osm/L) but hypotonic in plasma due to metabolism of anions, making it suitable for maintenance fluid therapy. Use caution in patients with renal impairment due to potassium content (13 m Eq/L). Not for co-administration with blood products via same tubing due to calcium content (5 m Eq/L).
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This solution provides fluids and electrolytes to maintain hydration and balance.,It contains potassium; follow dietary restrictions if you have kidney problems.,Report any signs of fluid overload (swelling, shortness of breath) or electrolyte imbalances (muscle cramps, weakness, irregular heartbeat).,Do not eat or drink anything unless instructed by your healthcare provider during infusion.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 IN PLASTIC CONTAINER is classified as Category C. No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.